top of page

Optiscan Imaging gets speaking gig at key health conferences

Optiscan Imaging’s pen-sized digital microscope is aiming to revolutionise healthcare. Credit: File

ASX-listed Optiscan Imaging has been invited to present its remarkable confocal endomicroscopic medical imaging technology at two key international conferences in North and South America. Managing director Dr Camile Farah will present to two groups of medical professionals in Canada and Brazil, firstly at the International Conference of the American Head and Neck Society in Montreal and then at the 48th Brazilian Congress of Stomatology and Oral Pathology in Curitiba.

The Montreal conference will see the company’s “Image Guided Oral Diagnosis using Confocal laser Endomicroscopy” presentation delivered to 1500 leading head and neck surgeons.

In Curitiba Dr Farah will unveil a “Real-Time Optical Microscopy of Oral Mucosal Lesions using Confocal Laser Endomicroscopy” presentation to a 1000 strong group of dentists, oral physicians and pathologists.

The potential of our unique and cutting-edge imaging technology for head and neck surgeons and oral physicians and pathologists is significant. I am looking forward to connecting with delegates across both continents and gaining further insights and understanding of their needs in refinement of our US commercial hub and expected launch of our InVivage intra-oral digital microscope in 2024. Optiscan Imaging managing director and chief executive officer Dr Camile Farah

The company also believe the conferences provide an opportunity to highlight recent developments in telepathology and machine learning and to discuss potential collaborations and partnerships.

Optiscan’s patented imaging technology houses miniaturised componentry to create a pen-sized digital microscope that offers the power of real-time 3D single-cell imaging – all in the palm of your hand.

The microscopic technology can make a real time diagnosis in-situ rather than the old system of taking a biopsy that then needs to be sent to a pathology lab for analysis.

Optiscan is nudging closer to obtaining highly-coveted marketing approval from the powerful United States Food and Drug Administration (FDA) for the use of its “InVivage” imaging device for oral cancer screening – an endorsement that will have it hurtling closer to breaking into that nation’s lucrative health-care market.

In May, Optiscan launched an entitlement offer aiming to raise $16.7 million as it looks to fast-track development and commercialisation of its devices. The funds will also be used to improve its artificial intelligence and telepathology capabilities and to undertake additional clinical studies to satisfy the FDA.

In a solid show of support, two of Optiscan’s cornerstone investors fully-subscribed to their entitlements under the pro-rata offer of one fully-paid ordinary share for every three shares held and have elected to collectively underwrite an additional $9.8 million slice of the offer.

Despite rapid advances in the tech space, many medical diagnostic procedures remain complex, invasive and time-consuming, often requiring collaboration between multiple clinicians within a larger healthcare network system.

Optiscan probes are fibre optic fluorescence confocal microscopes that are built for instant digital solutions in the medical and life-science imaging sectors. Images are generated by simply touching the probe against the tissue of interest.

Confocal microscopes are a particular type of microscope that collects light from a small spot on the specimen to provide greater resolution.

The company says InVivage has the ability to distinguish between normal, precancerous and cancerous tissue. Early imaging studies conducted at the Australian Centre for Oral Oncology Research and Education correctly diagnosed 100 per cent of cancer cases using Optiscan’s probe with an on-the-fly clinical assessment of its images in real-time.

Further studies are being conducted into the use of the device for detecting breast cancer, with a 42-patient trial at the Royal Melbourne Hospital.

Notably, one-third of all breast cancer patients who have lumpectomies return for second-stage surgeries and wider resections. Optiscan is confident its InVivage microscope can diagnose cancerous cells in real-time, enabling surgeons to clear the tumour in the first resection, drastically improving patient outcomes.

The company is also in the throes of developing digital pathology platforms to enable real-time collaboration between surgeons and pathologists. Management recently inked an exclusive collaboration with Canadian software developer Prolucid Technologies to develop AI algorithms using its medical images to enable immediate clinical decision-making.

Optiscan appears to have plenty going on right now and its invitation to speak at the latest two conferences will see it pitch its products directly to potential end users.

Is your ASX-listed company doing something interesting? Contact:



bottom of page